RhumbLine Advisers
AVIR icon

RhumbLine Advisers’s Atea Pharmaceuticals AVIR Stock Holding History

RhumbLine Advisers’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$459K Sell
88,042
-3,082
-3% -$15.8K ﹤0.01% 2782
2026
Q2 		$424K Buy
91,124
+2,070
+2% +$10.3K ﹤0.01% 2866
2026
Q1 		$479K Sell
89,054
-4,922
-5% -$22.6K ﹤0.01% 2643
2025
Q4 		$335K Sell
93,976
-19,636
-17% -$62.4K ﹤0.01% 2903
2025
Q3 		$329K Sell
113,612
-5,808
-5% -$19.8K ﹤0.01% 2938
2025
Q2 		$430K Buy
119,420
+2,977
+3% +$8.88K ﹤0.01% 2784
2025
Q1 		$348K Sell
116,443
-13,353
-10% -$41.7K ﹤0.01% 2799
2024
Q4 		$435K Sell
129,796
-3,318
-2% -$11K ﹤0.01% 2760
2024
Q3 		$446K Sell
133,114
-4,484
-3% -$16.3K ﹤0.01% 2772
2024
Q2 		$455K Sell
137,598
-4,304
-3% -$16K ﹤0.01% 2750
2024
Q1 		$573K Sell
141,902
-5,214
-4% -$20.4K ﹤0.01% 2578
2023
Q4 		$449K Buy
147,116
+12,808
+10% +$38.8K ﹤0.01% 2728
2023
Q3 		$403K Sell
134,308
-6,747
-5% -$23K ﹤0.01% 2738
2023
Q2 		$528K Buy
141,055
+17,368
+14% +$65K ﹤0.01% 2653
2023
Q1 		$414K Buy
123,687
+5,594
+5% +$22.7K ﹤0.01% 2501
2022
Q4 		$568K Buy
118,093
+1,979
+2% +$10K ﹤0.01% 2404
2022
Q3 		$661K Buy
116,114
+6,402
+6% +$49K ﹤0.01% 2368
2022
Q2 		$779K Buy
109,712
+27,475
+33% +$188K ﹤0.01% 2262
2022
Q1 		$594K Sell
82,237
-4,002
-5% -$27.2K ﹤0.01% 2345
2021
Q4 		$771K Buy
86,239
+547
+0.6% +$8.52K ﹤0.01% 2322
2021
Q3 		$3M Buy
85,692
+3,596
+4% +$100K ﹤0.01% 1661
2021
Q2 		$1.76M Buy
82,096
+64,933
+378% +$1.95M ﹤0.01% 2009
2021
Q1 		$1.06M Buy
17,163
+4,647
+37% +$314K ﹤0.01% 2167
2020
Q4 		$523K Buy
+12,516
New +$403K ﹤0.01% 2427

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Auour Investments
Auour Investments Woburn, Massachusetts $353M AUM 8.66% 1-Year Est. Return

RhumbLine Advisers's AVIR Position: Q3 2026 in Review

RhumbLine Advisers reduced its Atea Pharmaceuticals (AVIR) stake by 3.4% in Q3 2026, selling an estimated $15.8K and leaving 88,042 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

RhumbLine Advisers first reported a position in AVIR in Q4 2020 and has held it in 24 quarters since. The position peaked at $3M in Q3 2021. 56 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • RhumbLine Advisers held 88,042 shares of Atea Pharmaceuticals worth $459K as of Q3 2026.
  • RhumbLine Advisers sold 3,082 Atea Pharmaceuticals shares in Q3 2026, an estimated $15.8K.
  • Atea Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2782 holding.
  • RhumbLine Advisers first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • RhumbLine Advisers's Atea Pharmaceuticals position peaked at $3M in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.